诺瓦瓦克斯医药

NVAX NASDAQ
4.530
-0.070
-1.52%
盘后: 4.530 0 0.00% 17:07 07/23 EDT
开盘
4.560
昨收
4.600
最高
4.750
最低
4.500
成交量
51.49万
成交均量(3M)
82.52万
52周最高
51.60
52周最低
4.380
换手率
2.19%
市值
1.06亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供诺瓦瓦克斯医药 NVAX股票价格,诺瓦瓦克斯医药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
展开 >

最近浏览

名称
价格
涨跌幅